| Autor: |
Jingyuan Mao, Jian Zhang, Carolyn S.P. Lam, Mingjun Zhu, Chen Yao, Shutao Chen, Zhongyong Liu, Fengrong Wang, Yonggang Wang, Xiaohua Dai, Tianfu Niu, Dongqing An, Yang Miao, Tao Xu, Bo Dong, Xiaofeng Ma, Fengru Zhang, Xiaolong Wang, Ruihong Fan, Yingqiang Zhao, Tiemin Jiang, Yuhui Zhang, Xianliang Wang, Yazhu Hou, Zhiqiang Zhao, Quan Su, Junhua Zhang, Baohe Wang, Boli Zhang |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
ESC Heart Failure, Vol 7, Iss 6, Pp 3881-3890 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2055-5822 |
| DOI: |
10.1002/ehf2.12980 |
| Popis: |
Abstract Aims Qishen Yiqi dripping pills (QSYQ) may be beneficial in patients with ischaemic heart failure (IHF). We aimed to assess the efficacy and safety of QSYQ administered together with guideline‐directed medical therapy in patients with IHF. Methods and results This prospective randomized, double‐blind, multicentre placebo‐controlled study enrolled 640 patients with IHF between March 2012 and August 2014. Patients were randomly assigned to receive 6 months of QSYQ or placebo in addition to standard treatment. The primary outcome was 6 min walking distance at 6 months. Among the 638 IHF patients (mean age 65 years, 72% men), the 6 min walking distance increased from 336.15 ± 100.84 to 374.47 ± 103.09 m at 6 months in the QSYQ group, compared with 334.40 ± 100.27 to 340.71 ± 104.57 m in the placebo group (mean change +38.32 vs. +6.31 m respectively; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text